The EU health policy landscape is shifting fast and the implications for pharma launch planning, pricing and market access (P&MA), and commercial strategy are significant.
With EU Pharmaceutical Legislation reform and the Critical Medicines Act taking shape, companies are facing new questions around launch obligations, supply resilience, procurement, and access strategy.
Watch our webinar recording, where our EU HTA and Health Policy team is joined by legal and payer experts to discuss the latest EU policy developments and what they mean for pharma companies operating in Europe.
Drawing on recent interviews with senior pharma representatives across companies of varying sizes, market footprints, and portfolio profiles, our panel explores the opportunities, risks, and strategic choices emerging from this evolving policy landscape.
Key discussion topics:
- The EU Pharmaceutical Legislation reform: including early interpretations of launch obligations following Member State requests, and what emerging supply resilience requirements could mean for pharma companies
- The Critical Medicines Act: including the role of EU-level joint procurement mechanisms and their potential implications for drug procurement and supply strategies
- Strategic implications for pharma: including cross-stakeholder perspectives on how policy shifts may affect P&MA and commercial strategy, with reactions and analysis from industry, legal, and payer viewpoints
Don’t miss the opportunity to gain a clear understanding of where EU policy is heading, what it means for launch and access strategy, and where companies may need to act now to stay ahead of a rapidly evolving landscape.
